14.68
Schlusskurs vom Vortag:
$14.56
Offen:
$14.63
24-Stunden-Volumen:
257.06K
Relative Volume:
0.34
Marktkapitalisierung:
$576.81M
Einnahmen:
$128.29M
Nettoeinkommen (Verlust:
$-30.69M
KGV:
-17.90
EPS:
-0.82
Netto-Cashflow:
$-27.17M
1W Leistung:
+2.58%
1M Leistung:
-44.69%
6M Leistung:
-71.84%
1J Leistung:
-72.42%
Rxsight Inc Stock (RXST) Company Profile
Firmenname
Rxsight Inc
Sektor
Branche
Telefon
949-521-7822
Adresse
100 COLUMBIA STREET, ALISO VIEJO
Vergleichen Sie RXST mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RXST
Rxsight Inc
|
14.69 | 576.81M | 128.29M | -30.69M | -27.17M | -0.82 |
![]()
ABT
Abbott Laboratories
|
130.33 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
102.34 | 138.41B | 17.55B | 2.03B | 2.37B | 1.37 |
![]()
SYK
Stryker Corp
|
368.82 | 129.62B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
84.73 | 107.76B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
75.73 | 40.53B | 5.54B | 4.18B | 259.90M | 7.00 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-15 | Eingeleitet | Piper Sandler | Neutral |
2025-04-09 | Herabstufung | UBS | Buy → Neutral |
2025-04-04 | Herabstufung | JP Morgan | Overweight → Underweight |
2025-04-03 | Herabstufung | BofA Securities | Buy → Underperform |
2024-12-20 | Herabstufung | Stifel | Buy → Hold |
2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2024-12-06 | Eingeleitet | UBS | Buy |
2024-10-29 | Eingeleitet | Jefferies | Buy |
2024-08-20 | Bestätigt | Needham | Buy |
2024-08-06 | Bestätigt | Needham | Buy |
2024-05-07 | Bestätigt | BTIG Research | Buy |
2023-12-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-12-12 | Eingeleitet | Stifel | Buy |
2023-12-04 | Eingeleitet | Morgan Stanley | Overweight |
2023-04-13 | Eingeleitet | Oppenheimer | Outperform |
2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2022-04-08 | Eingeleitet | Needham | Buy |
Alle ansehen
Rxsight Inc Aktie (RXST) Neueste Nachrichten
Russell Investments Group Ltd. Sells 94,412 Shares of RxSight, Inc. (NASDAQ:RXST) - Defense World
JPMorgan Chase & Co. Reduces Stake in RxSight, Inc. (NASDAQ:RXST) - Defense World
RxSight, Inc. (NASDAQ:RXST) Given Average Recommendation of “Hold” by Brokerages - Defense World
RxSight Inc [RXST] Records 50-Day SMA of $23.43 - knoxdaily.com
What Does RxSight, Inc.'s (NASDAQ:RXST) Share Price Indicate? - Yahoo Finance
RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025 - The Manila Times
RxSight, Leading Eye Surgery Tech Company, Sets Q1 2025 Earnings Release Date - Stock Titan
LPL Financial LLC Boosts Holdings in RxSight, Inc. (NASDAQ:RXST) - Defense World
Geode Capital Management LLC Has $28.57 Million Stock Position in RxSight, Inc. (NASDAQ:RXST) - Defense World
Piper Sandler Initiates Coverage of RxSight (RXST) with Neutral Recommendation - Nasdaq
This Aurora Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday - Benzinga
Piper Sandler Initiates RxSight at Neutral With $18 Price Target - marketscreener.com
Piper Sandler Begins Coverage of RxSight (RXST) with Neutral Rat - GuruFocus
Piper Sandler sets RxSight stock target at $18, stays neutral By Investing.com - Investing.com South Africa
Piper Sandler sets RxSight stock target at $18, stays neutral - Investing.com
Piper Sandler Starts RxSight Inc. (RXST) at Neutral - StreetInsider
RxSight price target lowered to $17 from $22 at Wells Fargo - MSN
RxSight plunges after guidance cut; BofA downgrades - MSN
RxSight stock plunges to 52-week low at $14.24 amid market challenges By Investing.com - Investing.com South Africa
RxSight stock plunges to 52-week low at $14.24 amid market challenges - Investing.com
RxSight, Inc. (NASDAQ:RXST) Position Lifted by Vanguard Group Inc. - The AM Reporter
UBS cuts RxSight stock rating to neutral, slashes price target to $16 By Investing.com - Investing.com South Africa
RxSight downgraded at UBS after Q1 miss and guidance cut - MSN
RxSight stock downgraded at UBS on guidance cut (RXST:NASDAQ) - Seeking Alpha
Needham Cuts Price Target on RxSight to $22 From $43, Keeps Buy Rating - MarketScreener
UBS Downgrades RxSight to Neutral From Buy, Cuts Price Target to $16 From $45 - MarketScreener
UBS cuts RxSight stock rating to neutral, slashes price target to $16 - Investing.com Australia
UBS Downgrades RxSight Inc. (RXST) to Neutral - StreetInsider
RxSight at Needham Conference: Strategic Adjustments Amid Market Challenges By Investing.com - Investing.com Canada
Analysts Are Neutral on Top Healthcare Stocks: RxSight (RXST), Johnson & Johnson (JNJ) - The Globe and Mail
Needham & Company LLC Reiterates “Buy” Rating for RxSight (NASDAQ:RXST) - Defense World
Rxsight adjusts 2025 revenue guidance to $160M-$175M amid premium IOL market challenges - MSN
Midday Stock Roundup: Masimo, Virgin Galactic an Others Take Dives - Orange County Business Journal
JP Morgan downgrades RxSight on market, competitive pressures - Investing.com
JPMorgan Downgrades RxSight to Underweight From Overweight, Adjusts Price Target to $17 From $40 - MarketScreener
Deep Dive Into RxSight Stock: Analyst Perspectives (12 Ratings) - Benzinga
RxSight’s preliminary Q1 2025 revenue expected to increase 28% - Medical Buyer
American Express, Rxsight, Vertiv Holdings - TradingView
RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Strong Year-Over-Year Growth Amid Revised ... By GuruFocus - Investing.com Canada
JPMorgan Double Downgrades RxSight Inc. (RXST) to Underweight - StreetInsider
RxSight Faces Market Challenges As Revenue Guidance Drops - Finimize
RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade) - Seeking Alpha
JPMorgan cuts RxSight stock rating, slashes price target to $17 By Investing.com - Investing.com South Africa
JPMorgan cuts RxSight stock rating, slashes price target to $17 - Investing.com
RxSight stock plunges to 52-week low at $15.84 amid market challenges By Investing.com - Investing.com South Africa
RxSight stock plunges to 52-week low at $15.84 amid market challenges - Investing.com India
RxSight downgraded to Underweight from Overweight at JPMorgan - TipRanks
Earnings call transcript: RxSight Q1 2025 sees revenue growth, stock dips By Investing.com - Investing.com South Africa
RxSight Analyst Flags Growth Slowdown As Revised Outlook Misses Expectations - Benzinga
Biotech Shake-Up: Aldeyra Therapeutics & Others Feel The Heat - Finimize
RxSight plunges after guidance cut - MSN
Finanzdaten der Rxsight Inc-Aktie (RXST)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rxsight Inc-Aktie (RXST) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Fountain Tamara | Director |
Mar 12 '25 |
Sale |
25.71 |
7,000 |
180,002 |
24,793 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):